Aim: To examine the relative cost-effectiveness of predictive genetic tests for familial breast and ovarian cancer provided by Genetic Services of Western Australia.
Introduction
Inherited predisposition to cancer is thought to account for 5-10% of all cancer incidence 1 . Advances in genetic testing technology have many promising applications in health including improved diagnosis of disease and the earlier detection of genetic predisposition to adult-onset conditions, such as familial cancer. This will have important implications for resource allocation given the capacity to compare costs with associated benefits. Economic evaluation helps determine the relative value of new technology and enables better planning for the provision of future cancer genetic services.
In order to understand the relative cost-effectiveness of genetic testing the prevalence and penetrance of the gene mutation must be considered as well as the uptake and efficacy of available interventions to prevent or detect cancer early 2 . Reported benefits resulting from increased surveillance in women with a mutated BRCA gene have included earlier detection of breast cancer and an expected mortality reduction in women less than 50 years of age 3, 4 . There is also evidence that prophylactic intervention, such as bilateral mastectomy, has been associated with a reduction in the incidence of breast cancer of at least 90% 5 . Though there is evidence to suggest oophrectomy reduces risk of breast cancer, it is not within the scope of this study.
The absence of reliable surveillance methods for the early detection of ovarian cancer, and the poor prognosis following symptomatic presentation, have prompted many oncologists to recommend bilateral prophylactic salpingo-oophorectomy after childbearing 6, 7 . Furthermore, studies have validated the prophylactic role of surgical intervention and provided a convincing rationale for genetic testing in women with a strong family history 8, 9 .
This study aimed to evaluate the relative costs and outcomes of genetic testing for familial breast and ovarian cancer through Genetic Services of Western Australia (GSWA). The investigation included familial breast and ovarian cancers suitable for predictive DNA based testing on the basis of inherited BRCA 1/2 mutations. The theoretical cohorts simulated asymptomatic first-degree relatives of individuals with a known BRCA1/2 mutation, who had a 50% chance of inheriting the cancerpredisposing gene mutation.
Since reliable age and gene-specific cancer mortality data were not available at the time of modelling for relevant population subgroups, the impact of genetic testing and increased surveillance on mortality was not explored in this study. Instead the study focus was confined to the impact of genetic testing and increased surveillance on reduced cancer morbidity and, accordingly 'cancer-free years' was the most appropriate method to measure and report reduced cancer morbidity.
Methods

Models
Economic decision modelling software (TreeAge Data™ version 4.0) was used to develop a decision-analysis model, which mimicked the course of testing and treatment for women entering the Familial Cancer Program at GSWA. The attendance of women at high-risk of inherited breast or ovarian cancer in the program was adequate to warrant this study. Previous studies from which much of the data is derived also indicated women in this risk group merited further study.
Internet based searches were conducted using PubMed, Medline and Ovid on the costeffectiveness of genetic testing, cancer surveillance and surgical intervention to reduce cancer morbidity.
Markov models were used to predict the age of breast and ovarian cancer onset and costs of surveillance for carriers of a mutated BRCA1/2 cancer gene compared with non-mutation carriers and control subjects.
Each Markov cycle represented one year. The age and penetrance (or likelihood a person will develop cancer) relating to each cycle governed what proportion of women stayed in the 'well' state or shifted into the 'cancer' state. See Figure 1 .
Figure 1: Predictive genetic testing decision model for persons at high risk of familial breast cancer
Surveillance strategies modelled in this study (See Table 2 ) were based on the National Health and Medical Research Council (NHMRC) clinical practice guidelines for the detection and treatment of familial cancer 10, 11 and corroborated by Western Australian (WA) surgeons and oncologists working in the area. Accordingly, the models cover the period from age 25 to 70.
All women in the intervention group had predictive genetic testing to determine their mutation status. Inherited cancer segregates as an autosomal dominant trait, thus the offspring of a BRCA1/2 gene mutation carrier have a 1 in 2 chance of inheriting their cancer-predisposing mutation. Hence, half the women in the intervention group were deemed to be mutation positive and underwent intensive surveillance and prophylaxis as recommended. The other half were identified as mutation negative and only had population surveillance.
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Control Groups
Despite their high-risk family history, since control subjects did not undergo predictive genetic testing, their mutation status was unknown.
Women may or may not have increased their surveillance based on family history alone (perceived breast or ovarian cancer risk) so dichotomous scenarios were reviewed corresponding to surveillance extremes. For example, the intervention group (known mutation status) was compared with control subjects (unknown mutation status) having either intensive surveillance and prophylaxis, or population surveillance.
As a baseline for comparison we examined two scenarios corresponding to each extreme. The intervention group was first compared to control subjects (unknown mutation status) who adhered to clinical recommendations for increased surveillance based on their family history alone (control group 1). The intervention group was then compared with control subjects who have population or no surveillance, despite their high-risk family history (control group 2). The actual surveillance behaviour of control subjects was expected to be a mid-point between population surveillance or intensive surveillance and prophylaxis.
Costs
All costs are provided in Australian dollars and standardised to 2001-2002 prices using health index deflators 12 . Future costs were discounted at a rate of 5% per annum. Counselling, genetic testing, surveillance, surgery and treatment costs were based on patterns of care in WA and are consistent with NHMRC clinical practice guidelines for familial cancer 13 . Lifetime cancer treatment costs were taken from the Australian Institute of Health and Welfare 14 . Mean ages for surgery and cancer diagnosis were used to estimate years of discounting 15 , , , 16 17 18 .
Counselling costs were estimated in accord with GSWA and based on the average session time of Familial Cancer Program patients. Hourly costs were assigned based on staff and office requirements. Since diagnostic tests are required to confirm an index case before cascade testing is possible, a diagnostic cost component was also included.
Genetic testing costs were provided by the Molecular Genetic Laboratory, Princess Margaret Hospital. Cancer prevention and prophylaxis costs were provided by costing centres in Perth's major teaching hospitals based on a breakdown (pathology, medical, nursing, allied health and other) of surgical procedures in 2001-2002 and averaged to provide an estimate. Though capital expenditure was not assessed, a review of total WA health expenditure in 1999-2000 indicates this component would be less than 5% 19 .
Indirect costs were not included.
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Outcome data
Outcomes on the effectiveness of cancer screening and interventions on cancer incidence in these high risk individuals were derived from the published literature. Age-related 'population risk' of breast cancer represented national rates in 2000 20 . To enable comparisons between the simulated cohorts breast and ovarian cancer were examined separately and the risks of developing the two cancers were assumed to be independent.
Cumulative age-related cancer incidence in mutation carriers, with and without the recommended clinical intervention, were gathered from previous studies and factored for attrition, and hence took account of all-cause mortality. The age-specific 'inherited risk' of breast cancer in BRCA1/2 mutation-carriers was based on 65% or 45% penetrance respectively by age 70 consistent with studies by Antoniou et al 21 . The age-specific 'inherited risk' of ovarian cancer in mutation-carriers was based on 39% or 11% penetrance for BRCA1/2 respectively by age 70, as previously reported 22 .
The simulated population represented offspring of known mutation-carriers (at 50% risk of inheriting the gene mutation) and assumed full compliance with NHMRC clinical recommendations for intervention 23 .
Interventions modelled on behalf of population or intensive surveillance and prophylaxis are listed in Table 1 . For each intervention the optimal age, required frequency of an event and the non-discounted cost is reported.
Based on trends in WA, it was assumed that around 30% 24 of the breast intervention group would elect prophylactic bilateral mastectomy at a mean age of 38 years, with a lifetime reduction in breast cancer risk of 90% 25, 26 since many women elect surveillance but no surgery, this option was examined within the model. Mammographic screening of women between 50-69 years has been shown to reduce their lifetime risk of breast cancer by 35% 27 . Previous studies indicated that the younger age of cancer diagnosis in women with BRCA mutations justified screening from an earlier age 28 , , , , 29 30 31 32 . On this basis it was presumed that mutation carriers aged 35 to 49 would also reduce their lifetime risk of breast cancer by 35% though mammographic screening and clinical breast examination.
The available screening measures for ovarian cancer, such as transvaginal ultrasound and serum CA-125, have limited sensitivity and specificity and may not reduce ovarian cancer mortality 33 . For this reason it was assumed that all women in the intervention group would undergo the recommended prophylactic salpingooophorectomy at age 40 and achieve a lifetime reduction in ovarian cancer risk of 96% as previously reported 34, 35 . Sensitivity analysis was used to test the effects of varying these outcomes.
Complications from medical intervention, intangible costs and benefits were not incorporated.
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Results
Costs associated with genetic testing, surveillance, prophylaxis and cancer treatment are listed in Table 1 . Estimated total surveillance costs are listed in Table 2 . 
Ovarian Cancer
Intensive surveillance and prophylaxis $7,981 $3,381 Population surveillance n/a n/a
Results of the cost-effectiveness analysis of genetic testing for familial breast cancer are shown in Figure 2 . The intervention group was compared to control subjects for the period modelled (age 25-70). Costs incurred in the future have been discounted.
_____________ 73
Intervention effectiveness was measured by the number of years that the onset of cancer is delayed. Compared to control subjects undergoing high-level surveillance since their mutation status is unknown, targeted BRCA1 intervention provided total net savings of $1795 per woman and delayed the onset of breast cancer by 6 months. Likewise, BRCA2 intervention provided total net savings of $1681 and delayed cancer by 3 months.
Compared to control subjects having population surveillance, BRCA1 intervention incurred a total net cost of $3055 per woman but improved her outcome by 5.1 cancer-free years which is $601 per cancer-free year gained. Similarly, BRCA2 intervention delayed the onset of breast cancer by 3.2 years, at a total net cost of $3389 or, $1070 for each cancer-free year gained.
The cost-effectiveness analysis of genetic testing for familial ovarian cancer is shown in Figure 3 . Compared to control subjects undergoing no surveillance, BRCA1 intervention incurred a $1630 total net cost but delayed the onset of ovarian cancer by 3.5 years ($477 per cancer-free year gained); BRCA2 intervention incurred $2509 total net cost for a gain of 1.2 cancer-free years, ($2150 per cancer-free year gained).
Sensitivity Analysis
One-way sensitivity analysis was utilised to check the stability of the outcome given uncertainty in some variables, specifically the penetrance of BRCA mutations. Since this varied widely in the published literature 36 cumulative cancer incidence by age 70 was explored using reported confidence intervals 37 . The results shown in Table 3 indicated that a higher level of penetrance would provide the intervention group with increased effectiveness (cancer-free years gained) for a lower net cost or greater net savings compared to no genetic testing. The estimated number of women that elect prophylactic bilateral mastectomy to prevent breast cancer in Western Australia (30%) is low compared to the uptake in The Netherlands (51%) 38 . The impact on cost-effectiveness of higher uptake was examined in the breast models (see Table 4 ). A greater uptake of prophylactic mastectomy in high-risk women compared to surveillance alone was found to increase the cost-effectiveness of genetic testing. The impact of various discount rates (0, 3%, 5% and 7%) on the net cost or saving in the breast (BRCA1) intervention group was examined in Table 5 . The application of a 3% discount rate instead of the 5% rate utilised would increase per person net savings by $892 or, increase the per person net cost by $495 for the period observed, depending on the surveillance undertaken by control subjects. Findings were similar for the ovarian intervention group when the discount rate was adjusted (not shown).
Discussion
Early detection and intervention strategies resulting from predictive genetic testing for BRCA1/2 mutations in Western Australia has been demonstrated to be a costeffective use of resources under a range of scenarios.
Genetic testing enables the restriction of intensive surveillance to individuals with an identified BRCA1/2 gene mutation, leading to large net savings for the period observed (age 25-70). Compared with control subjects undergoing intensive surveillance and prophylaxis, the ovarian intervention group provided total net savings of $980-$1008 per woman. The breast intervention group provided total net _____________ 76
savings of $1681-$1795 per woman and delayed the onset of breast cancer (6mths BRCA1, 3mths BRCA2).
Compared to control subjects undergoing only population surveillance, it was predicted the onset of cancer could be delayed in the genetic testing intervention group. For example, breast cancer could be delayed at a total net cost of $3055 (5.1yrs) to $3389 (3.2yrs) for women with identified BRCA1/2 mutations. This is a cost of $601 or $1070 per cancer-free year gained. Since population surveillance is not currently recommended for ovarian cancer, control subjects undergoing no surveillance were compared with women in the intervention group who were expected to delay the onset of ovarian cancer at a net cost of $1630 (3.5yrs) to $2509 (1.2years) for women with BRCA1/2 mutations. This is a cost of $477 or $2150 per cancer-free year gained.
These findings are consistent with a study by Tengs and Berry 39 which found BRCA testing of high-risk women to be cost-effective, with estimated savings of $3400-$4700 per quality-adjusted life-year gained in a 30-year-old woman. Grann et al 40 also found genetic screening women to be cost-effective in Ashkenazi Jewish, but only if known mutation-carriers underwent the recommended prophylaxis. In the current study, genetic testing for BRCA mutations was found to be cost-effective even if women elected increased surveillance but declined surgery.
In addition to the reduction of cancer morbidity, benefits of predictive genetic testing include reduced anxiety from an unknown genetic background and the ability to make proactive decisions regarding medical and lifestyle options to prevent or minimise the risk of breast or ovarian cancer. The confirmation of risk status may also have important implications for family planning.
Although intangible costs and benefits were not explored in this study, aspects such as the psychological impact of extreme surgery, particularly bilateral mastectomy, on body image and sexuality warrants concern. However, a study by Hatcher et al found bilateral prophylactic mastectomy in women with high familial risk reduced psychological morbidity and anxiety and did not have a detrimental impact on women's body image or sexual functioning. They noted that women who chose such surgery had undergone more investigative tests than women who declined and had a higher, often inaccurate, perception of their risk of developing breast cancer 41 . Given the complexity of genetic risk communication this finding was not unexpected since confirmation as a BRCA mutation-carrier provides no certainty when, or if, cancer will occur in an individual, nor can a negative BRCA mutation result guarantee an individual will not develop cancer.
For clarity and comparison purposes the models were cancer and mutation specific. This represented a limitation of the study since some women may develop both breast and ovarian cancer and rarely carry both BRCA1 and BRCA2 mutations. We also assumed high-level patient compliance with clinical recommendations for intervention since the cost-effectiveness of genetic testing depends on compliance.
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The value of regular surveillance in women with a genetic or familial predisposition to breast cancer is uncertain 42 although many studies have indicated a potential benefit for young women with a family history of cancer 43 , , , 44 45 46 . Other research suggested screening may be less effective since women with these mutations were more likely to develop cancer before menopause when breast tissue was dense, making it difficult to detect tumours on a mammogram 47 . Additionally the rate of growth of breast cancer is often faster in younger women, which can also decrease the effectiveness of screening at regular intervals 48 .
Findings by Kreige et al 49 indicated magnetic resonance imaging was more sensitive than mammography for detecting beast cancers in women at increased risk because of inherited susceptibility. It is hoped that future research will provide clarity on the efficacy of intensive breast or ovarian cancer surveillance in known mutation-carriers.
The success of a genetic screening program however is dependent largely upon the compliance of clients with clinical recommendations for surveillance and the disclosure of mutation status by the proband to genetic relatives. In addition, the uptake of prophylactic surgery varies greatly between nations. In the Netherlands 51% of asymptomatic mutation carriers opted for bilateral mastectomy and 64% for oophorectomy 50 while the proportion of mutation-carriers that elect prophylaxis in Western Australia is around 30% 51 .
According to Grann et al 52 screening for BRCA mutations in the Ashkenazi Jewish population is only cost-effective if all women who tested positive underwent prophylactic surgery. However, this approach is complicated by prophylactic mastectomy not being totally protective, since breast cancer has been documented in women following prophylactic surgery 53, 54 and evidence that genetic information may even reduce motivation to change health behaviour 55 . Scheuer 56 found that genetic counselling and testing increased compliance with surveillance and led to riskreducing operations and diagnosis of early-stage tumours in patients with BRCA1/2 mutations.
Investigation into the uptake of prophylactic surgery in Australia, the impact of cultural differences and support in the medical sector for such interventions may provide insight into levels of patient compliance with clinical recommendations and help shape future intervention protocols.
Early detection and intervention through predictive genetic testing for BRCA mutations in Western Australia has been demonstrated to be a relatively cost-effective use of resources under a range of scenarios, though further studies are needed to verify the results of long-term gains and, or costs from genetic testing. Additional research into compliance with clinical recommendations for surveillance, the disclosure of risk information to relatives and the degree of community support for such programs is required, since the cost-effectiveness of genetic testing will depend on the value of this information to patients and society.
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